Study of CRB-701 for throat cancer that has returned or spread
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial tests a new drug called CRB-701 for people with a type of throat cancer (oropharyngeal squamous cell carcinoma) that has come back or spread and has not improved with standard treatments. The study compares CRB-701 to the doctor's choice of other treatments to see which works better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have throat cancer that started in the tonsils, base of tongue, soft palate, or back of the throat, and it has spread or come back and cannot be cured with standard treatments.
- You have already had at least one type of standard treatment (like chemotherapy and/or immunotherapy) and your cancer has grown or returned after that treatment.
- You are able to take care of yourself (ECOG performance status 0 or 1).
- You have at least one tumor that can be measured on scans and has not been previously treated with radiation, unless it has clearly grown after radiation.
- You are expected to live at least 12 weeks.
- You do not have serious eye problems, nerve damage, or other major health issues that would make the study unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving chemotherapy or chemotherapy plus immunotherapy before surgery can improve outcomes for people with advanced head and neck cancer that has come back or not gone away after prior treatment.
This trial tests a new drug, CRB-701, for people with advanced solid tumors that have a protein called nectin-4 on their surface. It might be an option if other treatments have stopped working or are not available.
This trial tests a combination of drugs (tislelizumab, cetuximab, and chemotherapy) given before surgery to treat mouth or throat cancer that has come back. The goal is to shrink the tumor and improve surgery outcomes.
This trial tests whether adding cetuximab to the standard drug pembrolizumab works better for head and neck cancer that has spread or come back after treatment. It is for people whose cancer did not respond to platinum chemotherapy and whose tumors have a certain immune marker (PD-L1).
This trial tests whether adding targeted radiation (SBRT) to a combination of chemotherapy and immunotherapy before surgery can improve outcomes for people with advanced mouth or throat cancer. It aims to shrink the tumor more effectively before removal.
This study tests a new drug, CRB-601-01, for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and can help shrink tumors.
Hear when a new Oropharyngeal Carcinoma (OPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.